Novartis's Blockbuster Gilenya Cleared For Children And Adolescents In Europe
Executive Summary
Novartis's blockbuster MS drug is now approved for children and adolescent use in the EU as well as the US, as the big pharma continues to build its MS franchise in advance of the start of generic competition to Gilenya, expected sometime after mid-2019.